Impact Factor 2021: 3.041 (@Clarivate Analytics)
5-Year Impact Factor: 2.776 (@Clarivate Analytics)
Immediacy Index: 0.927
Impact Factor Rank: 10/24, Q2 (Tropical Medicine)
  • Users Online: 1672
  • Print this page
  • Email this page
Year : 2022  |  Volume : 15  |  Issue : 7  |  Page : 293-307

Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review

1 School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, India
2 School of Pharmacy and Life Sciences, Centurion University of Technology and Management, Odisha, India

Correspondence Address:
Rudra Narayan Sahoo
School of Pharmacy and Life Sciences, Centurion University of Technology and Management, Odisha
Login to access the Email id

Source of Support: The authors received no extramural funding for the study, Conflict of Interest: None

DOI: 10.4103/1995-7645.348156

Rights and Permissions

Visceral leishmaniasis (VL), also known as Kala-azar, is caused by Leishmania (L.) donovani complex, which includes L. donovani and L. infantum and is associated with a high death rate as compared to the cutaneous and subcutaneous form. Treatment of VL includes chemotherapeutic agents which are associated with some major hurdles like toxicities, parenteral administration, high cost, parasite resistance and stability. Hence, there is an urgent requirement to develop novel chemotherapeutic agents or repurposing of existing drugs against VL. Developing formulation of new chemical entity for the treatment of VL is laborious, time consuming and associated with huge financial burden. However, screening of existing chemotherapeutic agents is a good alternative to avail cost-effective treatment option for VL. Non-PEGylated liposome encapsulated doxorubicin (Myocet®) is proposed as an alternative treatment option for VL in this review article. Here, we covered the fundamental aspects of VL, loophole associated with available current treatment strategies and non-PEGylated liposome encapsulated doxorubicin as a novel alternative formulation for treating VL, as this liposomal delivery system of doxorubicin might passively target the intra- cellular regions of macrophage.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded103    
    Comments [Add]    

Recommend this journal